CA2387391A1 - Peptides derives d'antigene humain et leurs utilisations - Google Patents

Peptides derives d'antigene humain et leurs utilisations Download PDF

Info

Publication number: CA2387391A1
Authority: CA; Canada
Prior art keywords: cells; mammal; immunogenic peptide; peptides; sclc
Prior art date: 2001-05-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002387391A

Other languages

English (en)

Inventor

Jean-Pierre Farcet

Romain K. Gherardi

Anne Bourguin-Plonquet

Pierre Langlade-Demoyen

Francisco Garcia-Pons

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Assistance Publique Hopitaux de Paris APHP

Institut National de la Sante et de la Recherche Medicale INSERM

Institut Pasteur

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-08

Filing date

2002-05-08

Publication date

2002-11-08

2001-05-08 Priority claimed from CA002344768A external-priority patent/CA2344768A1/fr

2002-05-08 Application filed by Individual filed Critical Individual

2002-05-08 Priority to CA002387391A priority Critical patent/CA2387391A1/fr

2002-11-08 Publication of CA2387391A1 publication Critical patent/CA2387391A1/fr

Status Abandoned legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 183
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 102
239000000427 antigen Substances 0.000 title claims abstract description 18
108091007433 antigens Proteins 0.000 title claims abstract description 18
102000036639 antigens Human genes 0.000 title claims abstract description 18
210000004027 cell Anatomy 0.000 claims abstract description 77
230000002163 immunogen Effects 0.000 claims abstract description 39
206010041067 Small cell lung cancer Diseases 0.000 claims abstract description 33
230000002265 prevention Effects 0.000 claims abstract description 8
230000003961 neuronal insult Effects 0.000 claims abstract description 6
238000000034 method Methods 0.000 claims description 48
241000282414 Homo sapiens Species 0.000 claims description 45
241000124008 Mammalia Species 0.000 claims description 39
108090000623 proteins and genes Proteins 0.000 claims description 34
208000000587 small cell lung carcinoma Diseases 0.000 claims description 32
102000004169 proteins and genes Human genes 0.000 claims description 27
230000028993 immune response Effects 0.000 claims description 25
230000004044 response Effects 0.000 claims description 25
238000000338 in vitro Methods 0.000 claims description 23
229920001184 polypeptide Polymers 0.000 claims description 17
102000040430 polynucleotide Human genes 0.000 claims description 15
108091033319 polynucleotide Proteins 0.000 claims description 15
239000002157 polynucleotide Substances 0.000 claims description 15
239000012634 fragment Substances 0.000 claims description 14
238000001727 in vivo Methods 0.000 claims description 14
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 13
230000001939 inductive effect Effects 0.000 claims description 13
150000001413 amino acids Chemical class 0.000 claims description 12
210000002569 neuron Anatomy 0.000 claims description 11
230000001225 therapeutic effect Effects 0.000 claims description 10
238000010171 animal model Methods 0.000 claims description 9
210000004698 lymphocyte Anatomy 0.000 claims description 9
230000001173 tumoral effect Effects 0.000 claims description 8
230000037452 priming Effects 0.000 claims description 6
239000011324 bead Substances 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 5
239000013604 expression vector Substances 0.000 claims description 5
210000000066 myeloid cell Anatomy 0.000 claims description 5
210000000653 nervous system Anatomy 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
230000004936 stimulating effect Effects 0.000 claims description 5
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 4
230000006378 damage Effects 0.000 claims description 4
239000001963 growth medium Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
201000005989 paraneoplastic polyneuropathy Diseases 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
206010029260 Neuroblastoma Diseases 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
206010039491 Sarcoma Diseases 0.000 claims description 3
230000000259 anti-tumor effect Effects 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
201000001514 prostate carcinoma Diseases 0.000 claims description 3
230000000717 retained effect Effects 0.000 claims description 3
239000004793 Polystyrene Substances 0.000 claims description 2
230000004913 activation Effects 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
210000002865 immune cell Anatomy 0.000 claims description 2
239000004816 latex Substances 0.000 claims description 2
229920000126 latex Polymers 0.000 claims description 2
239000004005 microsphere Substances 0.000 claims description 2
LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 2
230000001537 neural effect Effects 0.000 claims description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
229920002223 polystyrene Polymers 0.000 claims description 2
229960005486 vaccine Drugs 0.000 claims description 2
239000003981 vehicle Substances 0.000 claims description 2
238000001514 detection method Methods 0.000 claims 2
238000001890 transfection Methods 0.000 claims 1
210000001744 T-lymphocyte Anatomy 0.000 abstract description 21
230000027455 binding Effects 0.000 abstract description 15
206010028980 Neoplasm Diseases 0.000 abstract description 11
239000002773 nucleotide Substances 0.000 abstract description 9
125000003729 nucleotide group Chemical group 0.000 abstract description 9
231100000433 cytotoxic Toxicity 0.000 abstract description 8
230000001472 cytotoxic effect Effects 0.000 abstract description 8
201000011510 cancer Diseases 0.000 abstract description 3
210000003061 neural cell Anatomy 0.000 abstract description 3
102000006539 ELAV-Like Protein 4 Human genes 0.000 description 36
108010008802 ELAV-Like Protein 4 Proteins 0.000 description 36
108020004414 DNA Proteins 0.000 description 19
102000053602 DNA Human genes 0.000 description 19
241000699670 Mus sp. Species 0.000 description 19
230000004048 modification Effects 0.000 description 11
238000012986 modification Methods 0.000 description 11
238000003556 assay Methods 0.000 description 10
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 8
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
108010088729 HLA-A*02:01 antigen Proteins 0.000 description 7
230000006641 stabilisation Effects 0.000 description 7
238000011105 stabilization Methods 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
230000009089 cytolysis Effects 0.000 description 6
230000006698 induction Effects 0.000 description 6
206010022000 influenza Diseases 0.000 description 6
239000000463 material Substances 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
108010002350 Interleukin-2 Proteins 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
239000012636 effector Substances 0.000 description 5
229920002477 rna polymer Polymers 0.000 description 5
239000012979 RPMI medium Substances 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
239000002243 precursor Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
239000013598 vector Substances 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
229930182816 L-glutamine Natural products 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
238000010367 cloning Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
210000004443 dendritic cell Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
238000009738 saturating Methods 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
101710132601 Capsid protein Proteins 0.000 description 2
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
206010011968 Decreased immune responsiveness Diseases 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
108010075704 HLA-A Antigens Proteins 0.000 description 2
102000011786 HLA-A Antigens Human genes 0.000 description 2
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
108091054437 MHC class I family Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
RGNOTKMIMZMNRX-XVFCMESISA-N 2-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-4-one Chemical compound NC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RGNOTKMIMZMNRX-XVFCMESISA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical class BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
WQLDNOCHHRISMS-NAKRPEOUSA-N Ala-Pro-Ile Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WQLDNOCHHRISMS-NAKRPEOUSA-N 0.000 description 1
MTDDMSUUXNQMKK-BPNCWPANSA-N Ala-Tyr-Arg Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N MTDDMSUUXNQMKK-BPNCWPANSA-N 0.000 description 1
101100148654 Arabidopsis thaliana SAB gene Proteins 0.000 description 1
YBZMTKUDWXZLIX-UWVGGRQHSA-N Arg-Leu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YBZMTKUDWXZLIX-UWVGGRQHSA-N 0.000 description 1
XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
101710125089 Bindin Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108091060211 Expressed sequence tag Proteins 0.000 description 1
SHAUZYVSXAMYAZ-JYJNAYRXSA-N Gln-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N SHAUZYVSXAMYAZ-JYJNAYRXSA-N 0.000 description 1
BRFJMRSRMOMIMU-WHFBIAKZSA-N Gly-Ala-Asn Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O BRFJMRSRMOMIMU-WHFBIAKZSA-N 0.000 description 1
JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
IXHQLZIWBCQBLQ-STQMWFEESA-N Gly-Pro-Phe Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IXHQLZIWBCQBLQ-STQMWFEESA-N 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
241000001642 Graus Species 0.000 description 1
108010074032 HLA-A2 Antigen Proteins 0.000 description 1
102000025850 HLA-A2 Antigen Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000896244 Homo sapiens ELAV-like protein 4 Proteins 0.000 description 1
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
KXUKTDGKLAOCQK-LSJOCFKGSA-N Ile-Val-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O KXUKTDGKLAOCQK-LSJOCFKGSA-N 0.000 description 1
101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 1
QDSKNVXKLPQNOJ-GVXVVHGQSA-N Leu-Gln-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QDSKNVXKLPQNOJ-GVXVVHGQSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
108010079364 N-glycylalanine Proteins 0.000 description 1
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
ZOGICTVLQDWPER-UFYCRDLUSA-N Phe-Tyr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O ZOGICTVLQDWPER-UFYCRDLUSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
GFHOSBYCLACKEK-GUBZILKMSA-N Pro-Pro-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O GFHOSBYCLACKEK-GUBZILKMSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102100040119 SH3 domain-binding protein 5 Human genes 0.000 description 1
MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
NSGZILIDHCIZAM-KKUMJFAQSA-N Tyr-Leu-Ser Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NSGZILIDHCIZAM-KKUMJFAQSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
108010043240 arginyl-leucyl-glycine Proteins 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
238000003766 bioinformatics method Methods 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
201000004559 cerebral degeneration Diseases 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000007402 cytotoxic response Effects 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
230000036541 health Effects 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
101150070413 htr4 gene Proteins 0.000 description 1
102000055192 human ELAVL4 Human genes 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000010185 immunofluorescence analysis Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
208000013537 paraneoplastic sensory ganglionopathy Diseases 0.000 description 1
244000045947 parasite Species 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229940068984 polyvinyl alcohol Drugs 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA002387391A 2001-05-08 2002-05-08 Peptides derives d'antigene humain et leurs utilisations Abandoned CA2387391A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002387391A CA2387391A1 (fr)	2001-05-08	2002-05-08	Peptides derives d'antigene humain et leurs utilisations

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CA002344768A CA2344768A1 (fr)	2001-05-08	2001-05-08	Peptides derives d'antigene humain et leurs utilisations
CA2,344,768		2001-05-08
CA002387391A CA2387391A1 (fr)	2001-05-08	2002-05-08	Peptides derives d'antigene humain et leurs utilisations

Publications (1)

Publication Number	Publication Date
CA2387391A1 true CA2387391A1 (fr)	2002-11-08

Family

ID=25682522

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002387391A Abandoned CA2387391A1 (fr)	2001-05-08	2002-05-08	Peptides derives d'antigene humain et leurs utilisations

Country Status (1)

Country	Link
CA (1)	CA2387391A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110280896A1 (en) *	2007-07-05	2011-11-17	Darnell Robert B	Methods and compositions for tumor vaccination and therapy

2002
- 2002-05-08 CA CA002387391A patent/CA2387391A1/fr not_active Abandoned

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110280896A1 (en) *	2007-07-05	2011-11-17	Darnell Robert B	Methods and compositions for tumor vaccination and therapy
US8193313B2 (en) *	2007-07-05	2012-06-05	The Rockefeller University	Methods and compositions for tumor vaccination and therapy

Publication	Publication Date	Title
JP3759738B2 (ja)	2006-03-29	免疫原性ペプチド
CA2383737C (fr)	2011-01-18	Peptides derives de muc-1
US7148326B2 (en)	2006-12-12	Tumor antigen
AU2008290061B2 (en)	2014-01-30	CDCA1 peptide and pharmaceutical agent comprising the same
JP2003521245A (ja)	2003-07-15	ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導
JP7026970B2 (ja)	2022-03-01	白血病およびその他のがんに対する免疫療法において使用するためのペプチドおよびペプチドの組み合わせ
WO2020145222A1 (fr)	2020-07-16	Nouveaux néoantigènes et immunothérapie anticancéreuse l'utilisant
JP2009195235A (ja)	2009-09-03	免疫エフェクター細胞ハイブリッド
Plonquet et al.	2003	Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human
CN117586344A (zh)	2024-02-23	靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
JP2003517310A (ja)	2003-05-27	ペプチドおよび核酸組成物を使用する、ｍａｇｅ２／３に対する細胞性免疫応答の誘導
WO2005068632A1 (fr)	2005-07-28	Epitope/peptide reconnu par ctl specifique de ep-cam a restriction hla-a2402 et son utilisation
AU3102299A (en)	1999-10-11	Compositions and methods for gene-based vaccines to provoke T cell responses
AU755156B2 (en)	2002-12-05	Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
CA2387391A1 (fr)	2002-11-08	Peptides derives d'antigene humain et leurs utilisations
CA2344768A1 (fr)	2002-11-08	Peptides derives d'antigene humain et leurs utilisations
AU767391B2 (en)	2003-11-06	Peptides related to an IGF-II-R epitope, polynucleotides encoding the peptides, and their use in immunomodulation
WO2000020457A9 (fr)	2002-04-25	Peptides apparentes a un epitope igf-ii-r, polynucleotides codant ces peptides, et utilisation de ceux-ci dans l'immunomodulation
CA2362295A1 (fr)	2000-08-17	Concatomeres de peptide antigene
JP2025508970A (ja)	2025-04-10	Ｈｌａ－ａ＊０２：０１制限ヒト前立腺酸性ホスファターゼ（ｐａｐ）エピトープとの反応性を示すヒトｔ細胞受容体対

Legal Events

Date	Code	Title	Description
2005-05-09	FZDE	Discontinued